Butler Hospital
- Type
- Teaching hospital
- Where
- Providence, RI
- Medicare CCN
- 414000
- Received
- $2,679,595 in 86 records, 2023 ($0 general, $2,679,595 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Butler Hospital Fuzzy (name and state)
- Federal award recipient: BUTLER HOSPITAL Fuzzy (name and state)
- Nonprofit: BUTLER HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | Research payment | 86 | $2,679,595 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eisai Inc. | 52 | $1,477,912 | 2023 |
| Biogen, Inc. | 2 | $381,090 | 2023 |
| Eli Lilly and Company | 3 | $374,226 | 2023 |
| Janssen Research & Development, LLC | 20 | $333,550 | 2023 |
| GE HEALTHCARE | 1 | $53,390 | 2023 |
| Genentech, Inc. | 7 | $49,425 | 2023 |
| Neuronetics, Inc. | 1 | $10,000 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 86 | $2,679,595 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-27 | Janssen Research & Development, LLC | $52,896 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-12-21 | Genentech, Inc. | $32,671 | Research payment | Cash or cash equivalent | Phase II study for Moderate AD | 2023 | |
| 2023-12-14 | Eisai Inc. | $46,387 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-12-01 | Eisai Inc. | $21,080 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-12-01 | Eisai Inc. | $10,955 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-12-01 | Eisai Inc. | $8,335 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-11-22 | Eisai Inc. | $35,604 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-11-02 | Neuronetics, Inc. | $10,000 | Research payment | Cash or cash equivalent | Neurostar TMS Therapy System Device, Neurostar TMS Therapy System | EMA-Guided Adaptive- Schedule TMS Maintenance Therapy | 2023 |
| 2023-11-01 | Genentech, Inc. | $1,485 | Research payment | Cash or cash equivalent | Phase II study for Moderate AD | 2023 | |
| 2023-10-23 | Janssen Research & Development, LLC | $1,533 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-10-19 | Eisai Inc. | $231,294 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-10-19 | Eisai Inc. | $33,567 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-10-06 | Janssen Research & Development, LLC | $8,512 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-10-01 | Eisai Inc. | $21,560 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-10-01 | Eisai Inc. | $20,580 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-10-01 | Eisai Inc. | $15,660 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-10-01 | Eisai Inc. | $11,955 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-10-01 | Eisai Inc. | $9,705 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-10-01 | Eisai Inc. | $7,710 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-09-21 | Eisai Inc. | $61,906 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-09-11 | Janssen Research & Development, LLC | $26,226 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-09-01 | Eisai Inc. | $26,660 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-09-01 | Eisai Inc. | $9,300 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-09-01 | Eisai Inc. | $5,330 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-09-01 | Janssen Research & Development, LLC | $5,099 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-08-29 | Eli Lilly and Company | $270,581 | Research payment | Cash or cash equivalent | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | 2023 | |
| 2023-08-18 | Eisai Inc. | $1,864 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-08-10 | Janssen Research & Development, LLC | $47,647 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-07-24 | Eisai Inc. | $73,641 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-07-10 | Janssen Research & Development, LLC | $22,163 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-07-07 | Janssen Research & Development, LLC | $2,438 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-07-03 | Janssen Research & Development, LLC | $8,837 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-07-01 | Eisai Inc. | $77,125 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-07-01 | Eisai Inc. | $26,590 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-07-01 | Eisai Inc. | $22,770 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-06-09 | Janssen Research & Development, LLC | $21,055 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-06-01 | Eli Lilly and Company | $103,155 | Research payment | Cash or cash equivalent | ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | 2023 | |
| 2023-06-01 | Janssen Research & Development, LLC | $8,597 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-05-19 | Eisai Inc. | $67,756 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-05-11 | Janssen Research & Development, LLC | $24,527 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-05-08 | Eisai Inc. | $26,458 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-05-04 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-05-01 | Eisai Inc. | $24,880 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-05-01 | Janssen Research & Development, LLC | $8,885 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-05-01 | Eisai Inc. | $8,540 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-05-01 | Eisai Inc. | $4,670 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-27 | GE HEALTHCARE | $53,390 | Research payment | In-kind items and services | Vizamyl Drug, CORE IMAGING | FLUTE-21-01B: BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers (TRACE-B) | 2023 |
| 2023-04-20 | Eisai Inc. | $1,222 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-04-20 | Genentech, Inc. | $119 | Research payment | Cash or cash equivalent | Phase II study for Moderate AD | 2023 | |
| 2023-04-20 | Genentech, Inc. | $119 | Research payment | Cash or cash equivalent | Phase II study for Moderate AD | 2023 | |
| 2023-04-13 | Eli Lilly and Company | $490 | Research payment | In-kind items and services | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | 2023 | |
| 2023-04-10 | Janssen Research & Development, LLC | $14,577 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-04-05 | Eisai Inc. | $61,393 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-04-01 | Eisai Inc. | $26,635 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-01 | Eisai Inc. | $14,120 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-01 | Eisai Inc. | $13,760 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-01 | Eisai Inc. | $9,135 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-01 | Eisai Inc. | $5,760 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-04-01 | Eisai Inc. | $5,320 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-03-24 | Janssen Research & Development, LLC | $3,882 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-03-14 | Genentech, Inc. | $6,773 | Research payment | Cash or cash equivalent | Phase II study for Moderate AD | 2023 | |
| 2023-03-01 | Eisai Inc. | $13,310 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-03-01 | Eisai Inc. | $2,600 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-03-01 | Eisai Inc. | $290 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-27 | Janssen Research & Development, LLC | $6,649 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-02-20 | Eisai Inc. | $57,479 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-02-20 | Janssen Research & Development, LLC | $3,331 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-02-03 | Janssen Research & Development, LLC | $57,177 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-02-01 | Eisai Inc. | $52,835 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $31,015 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $30,795 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $24,760 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $19,505 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $17,160 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $13,780 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $10,445 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $7,500 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-02-01 | Eisai Inc. | $5,160 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to | 2023 |
| 2023-01-30 | Janssen Research & Development, LLC | $9,014 | Research payment | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-01-20 | Biogen, Inc. | $358,221 | Research payment | Cash or cash equivalent | ADUHELM Biological, Neurology | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ | 2023 |
| 2023-01-20 | Eisai Inc. | $38,562 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-01-18 | Genentech, Inc. | $6,773 | Research payment | Cash or cash equivalent | Phase II study for Moderate AD | 2023 | |
| 2023-01-18 | Genentech, Inc. | $1,485 | Research payment | Cash or cash equivalent | Phase II study for Moderate AD | 2023 | |
| 2023-01-12 | Biogen, Inc. | $22,869 | Research payment | Cash or cash equivalent | ADUHELM Biological, Neurology | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ | 2023 |
| 2023-01-06 | Eisai Inc. | $103,266 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
| 2023-01-06 | Eisai Inc. | $216 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Providence, RI, county Providence County, RI, state Rhode Island; placed by its city name.
| Measure | Place (city or town) Providence, RI | County Providence County, RI | State Rhode Island |
|---|---|---|---|
| Population B01003 | 191,767 | 664,854 | 1,101,801 |
| Population, 2020 census P1 | 190,934 | 660,741 | 1,097,379 |
| Median age B01002 | 32.8 | 38.0 | 40.6 |
| Under 18 B01001 | 20.1% | 20.1% | 18.8% |
| 65 and over B01001 | 11.6% | 16.3% | 18.7% |
| Households B11001 | 71,497 | 259,210 | 441,570 |
| Foreign born B05002 | 33.5% | 20.9% | 15.3% |
| Median household income B19013 | $68,119 | $78,787 | $87,796 |
| Median family income B19113 | $80,994 | $99,120 | $112,375 |
| Per capita income B19301 | $37,138 | $41,523 | $47,150 |
| Poverty rate B17001 | 20.7% | 13.4% | 11.2% |
| Unemployment rate B23025 | 8.2% | 6.6% | 5.8% |
| Civilian labor force B23025 | 101,717 | 358,122 | 594,253 |
| Mean commute (minutes) B08013 | 25.0 | 25.9 | 25.5 |
| Bachelor's degree or higher B15003 | 34.6% | 32.3% | 37.7% |
| Housing units B25001 | 79,423 | 277,740 | 485,932 |
| Owner-occupied B25003 | 41.4% | 56.9% | 63.6% |
| Renters B25003 | 58.6% | 43.1% | 36.4% |
| Median home value B25077 | $362,200 | $373,600 | $404,200 |
| Median gross rent B25064 | $1,408 | $1,312 | $1,342 |
| White, not Hispanic B03002 | 33.1% | 56.5% | 68.0% |
| Black B03002 | 10.2% | 7.0% | 4.9% |
| Hispanic or Latino B03002 | 45.3% | 25.6% | 17.7% |
| Asian B03002 | 6.2% | 4.2% | 3.5% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Providence, RI.
Comments